Organogenesis Holdings Inc.

NasdaqCM:ORGO Voorraadrapport

Marktkapitalisatie: US$533.0m

Organogenesis Holdings Balans Gezondheid

Financiële gezondheid criteriumcontroles 6/6

Organogenesis Holdings heeft een totaal eigen vermogen van $278.5M en een totale schuld van $62.1M, wat de schuld-eigenvermogensverhouding op 22.3% brengt. De totale activa en totale passiva bedragen respectievelijk $446.3M en $167.7M. De EBIT Organogenesis Holdings is $11.9M waardoor de rentedekking 5.7 is. Het heeft contanten en kortetermijnbeleggingen van $94.3M.

Belangrijke informatie

22.3%

Verhouding schuld/eigen vermogen

US$62.12m

Schuld

Rente dekkingsratio5.7x
ContantUS$94.34m
AandelenUS$278.55m
Totaal verplichtingenUS$167.75m
Totaal activaUS$446.30m

Recente financiële gezondheidsupdates

Recent updates

Organogenesis: Lurking Disruption With Recovery To Follow

Oct 15

Why Investors Shouldn't Be Surprised By Organogenesis Holdings Inc.'s (NASDAQ:ORGO) Low P/S

Sep 09
Why Investors Shouldn't Be Surprised By Organogenesis Holdings Inc.'s (NASDAQ:ORGO) Low P/S

We Think Organogenesis Holdings Inc.'s (NASDAQ:ORGO) CEO Compensation Package Needs To Be Put Under A Microscope

Jun 15
We Think Organogenesis Holdings Inc.'s (NASDAQ:ORGO) CEO Compensation Package Needs To Be Put Under A Microscope

Organogenesis Holdings: Small-Cap Biotech With Inconsistent Earnings And A Powerful Catalyst

Jun 10

Investors Can Find Comfort In Organogenesis Holdings' (NASDAQ:ORGO) Earnings Quality

May 21
Investors Can Find Comfort In Organogenesis Holdings' (NASDAQ:ORGO) Earnings Quality

Shareholders Should Be Pleased With Organogenesis Holdings Inc.'s (NASDAQ:ORGO) Price

May 01
Shareholders Should Be Pleased With Organogenesis Holdings Inc.'s (NASDAQ:ORGO) Price

Is Organogenesis Holdings (NASDAQ:ORGO) Using Too Much Debt?

Apr 10
Is Organogenesis Holdings (NASDAQ:ORGO) Using Too Much Debt?

These 4 Measures Indicate That Organogenesis Holdings (NASDAQ:ORGO) Is Using Debt Reasonably Well

Jan 04
These 4 Measures Indicate That Organogenesis Holdings (NASDAQ:ORGO) Is Using Debt Reasonably Well

Is Organogenesis Holdings (NASDAQ:ORGO) Using Too Much Debt?

May 31
Is Organogenesis Holdings (NASDAQ:ORGO) Using Too Much Debt?

Does Organogenesis Holdings (NASDAQ:ORGO) Have A Healthy Balance Sheet?

Jan 19
Does Organogenesis Holdings (NASDAQ:ORGO) Have A Healthy Balance Sheet?

Organogenesis: Finding A Spot For This Regenerative Medicines Company In My 'Bio Boom' Portfolio

Oct 18

Here's Why Organogenesis Holdings (NASDAQ:ORGO) Can Manage Its Debt Responsibly

Sep 23
Here's Why Organogenesis Holdings (NASDAQ:ORGO) Can Manage Its Debt Responsibly

Organogenesis gets FDA clearance for PuraPly MZ for wound healing

Aug 15

Here's Why Organogenesis Holdings (NASDAQ:ORGO) Has Caught The Eye Of Investors

Jul 28
Here's Why Organogenesis Holdings (NASDAQ:ORGO) Has Caught The Eye Of Investors

Analyse van de financiële positie

Kortlopende schulden: De korte termijn activa ( $238.5M ) ORGO } overtreffen de korte termijn passiva ( $77.3M ).

Langlopende schulden: De kortetermijnactiva ORGO ( $238.5M ) overtreffen de langetermijnschulden ( $90.5M ).


Schuld/ eigen vermogen geschiedenis en analyse

Schuldniveau: ORGO heeft meer geld in kas dan de totale schuld.

Schuld verminderen: De schuld/eigen vermogen-ratio van ORGO is de afgelopen 5 jaar gedaald van 648.7% naar 22.3%.

Schuldendekking: De schuld van ORGO wordt goed gedekt door de operationele kasstroom ( 22.4% ).

Rentedekking: De rentebetalingen op de schuld van ORGO worden goed gedekt door EBIT ( 5.7 x dekking).


Balans


Ontdek gezonde bedrijven